Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease

Published: 06 Nov 2022

  • Views:

    Views Icon 448
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

AHA 22 - Dr Kate Wilcox, CardioNerds Academic Fellow (Medical College of Wisconsin, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr David L Preiss (University of Oxford, UK), investigator of the late-breaking EMPA-Kidney trial (NCT03594110).

The trial, first presented AHA 22, looked at the SGLT2i, empagliflozin's (Boehringer Ingelheim) effect on kidney disease progression or cardiovascular death compared to  placebo on top of standard of care in 6609 patients with pre-existing chronic kidney disease (CKD).

EMPA-Kidney demonstrated that the treatment with empagliflozin reduced kidney disease progression or CV death. 

For the longer version of this discussion with more information on methodology click here.

Access our full AHA 22 Scientific Coverage here.

Recorded remotely from Oxford and Milwaukee, 2022. 

Editor: Mirjam Boros
Video Specialist: Oliver Miles